Publicaciones en las que colabora con José Domingo Pedreira Andrade (26)

2015

  1. Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study

    PLoS ONE, Vol. 10, Núm. 10

  2. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

2013

  1. Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B

    AIDS, Vol. 27, Núm. 14, pp. 2219-2224

  2. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9

  2. Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients

    Retrovirology, Vol. 9

2008

  1. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313

2005

  1. Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1

    Clinical Infectious Diseases, Vol. 41, Núm. 2, pp. 227-232

  2. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients

    Journal of Medical Virology, Vol. 77, Núm. 1, pp. 23-28

  3. Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain

    Clinical Infectious Diseases, Vol. 41, Núm. 9, pp. 1350-1354

2004

  1. Consensus conference on chronic viral hepatitis and HIV infection: Updated Spanish recommendations

    Journal of Viral Hepatitis

2003

  1. Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients

    AIDS, Vol. 17, Núm. 7, pp. 1023-1028

2001

  1. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir

    AIDS, Vol. 15, Núm. 13, pp. 1701-1706

  2. Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy

    HIV Clinical Trials, Vol. 2, Núm. 5, pp. 429-437

2000

  1. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain

    AIDS, Vol. 14, Núm. 6, pp. 727-732

1999

  1. Hepatitis C and HTV infection: Biological, clinical, and therapeutic implications

    Journal of Hepatology, Supplement, Vol. 31, Núm. 1, pp. 119-123

1997

  1. A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients

    Journal of Infection, Vol. 35, Núm. 3, pp. 225-230

1996

  1. Circulating hepatitis C virus genotypes in Spain. The Hepatitis/HIV Spanish Study Group.

    Vox sanguinis, Vol. 70, Núm. 3, pp. 180-181

  2. Interferon α for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus

    Clinical Infectious Diseases, Vol. 23, Núm. 3, pp. 585-591

  3. TRATAMIENTO DE LA HEPATITIS CRONICA C CON INTERFERON EN PACIENTES INFECTADOS POR EL VIRUS DE LA INMUNODEFICIENCIA HUMANA

    Medicina Clinica, Vol. 106, Núm. 13, pp. 486-490